INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 166 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2018. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $183,000 | +76.0% | 1,446 | +16.2% | 0.00% | +100.0% |
| Q2 2018 | $104,000 | +35.1% | 1,244 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $77,000 | +2.7% | 1,244 | -3.1% | 0.00% | 0.0% |
| Q4 2017 | $75,000 | -8.5% | 1,284 | -9.4% | 0.00% | 0.0% |
| Q3 2017 | $82,000 | -44.2% | 1,417 | +16.5% | 0.00% | -50.0% |
| Q2 2017 | $147,000 | -2.0% | 1,216 | -8.1% | 0.00% | -33.3% |
| Q1 2017 | $150,000 | -3.8% | 1,323 | -8.1% | 0.00% | 0.0% |
| Q4 2016 | $156,000 | -75.0% | 1,439 | -62.1% | 0.00% | -72.7% |
| Q3 2016 | $625,000 | +15.3% | 3,800 | 0.0% | 0.01% | +10.0% |
| Q2 2016 | $542,000 | +11.1% | 3,800 | 0.0% | 0.01% | +11.1% |
| Q1 2016 | $488,000 | -14.1% | 3,800 | 0.0% | 0.01% | -10.0% |
| Q4 2015 | $568,000 | +2.0% | 3,800 | +13.1% | 0.01% | +11.1% |
| Q3 2015 | $557,000 | -65.1% | 3,360 | -49.1% | 0.01% | -18.2% |
| Q2 2015 | $1,594,000 | – | 6,600 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |